Knoa Pharma Appoints Michael Goettler

Knoa Pharma announced a leadership change on July 1, 2026. Knoa Pharma announced the appointment of Michael Goettler, who most recently served as CEO of Viatris, as President and Chief Executive Officer, effective July 6, 2026.

What changed

Michael Goettler was named President and Chief Executive Officer.

Leader: Michael Goettler
Role: President and Chief Executive Officer
Effective: July 6, 2026
Announcement date: July 1, 2026

Leadership background

Goettler most recently served as CEO of Viatris, a global healthcare company. The company said he brings more than 30 years of experience, has built and scaled innovative pharmaceutical businesses, and has held senior roles at leading companies including Sanofi and Pfizer. His leadership experience spans commercial operations, R&D, medical affairs, and global markets. He holds an MBA from the University of Texas at Austin and a graduate degree from the Koblenz School of Corporate Management in Germany.

The mandate

Knoa Pharma says its public health purpose is to help abate the opioid crisis. Board Chairman Dr. Norbert Riedel said Knoa Pharma will be well positioned under Goettler’s leadership to advance its public health purpose while responsibly meeting the needs of patients. Goettler said he looks forward to working alongside the talented team at Knoa to advance this mission, build a sustainable business, and make a meaningful difference for patients and communities across the country. He will also serve as the fifth member of the Knoa Pharma Board.

Why this matters for GTM teams

Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.

Source and methodology

This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.

Primary source: Knoa Pharma leadership announcement.